SCIENTIFIC RESEARCH

Our pipeline

Overview

Our pipeline of novel TRK modulators is presently focused on a multitude of dermatology and oncology disorders that are dependent on the dysregulation of the TRK signaling pathway. We are also exploring new therapeutic possibilities which will utilize TRK modulators across an array of diseases and conditions.

Dermatology

In Dermatology, we are developing a clinically-validated, first-in-class, selective TRK modulator, PBI-100, which contains anti-itch, anti-inflammatory and antiproliferative effects. We are developing PBI-100 for a range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis.

Oncology

In Oncology, where precision medicine strategies have been utilized for the treatment of various solid and liquid tumors, we are developing PBI-200, a best-in-class, orally active TRK inhibitor. PBI-200 is a highly brain penetrant agent which overcomes the acquired clinical resistance mutations that are observed with current TRK inhibitor therapies. It is intended to treat a broad range of genomically-defined solid tumor cancers, including primary and metastatic brain cancers.

PBI-100 – Dermatology

  • PRECLINICAL
  • IND ENABLING
  • PHASE I
  • PHASE II
Psoriasis
Atopic Dermatitis
Other Dermatoses

PBI-200 – Oncology

  • PRECLINICAL
  • IND ENABLING
  • PHASE I
  • PHASE II
TRK Fusion Cancers
Other Cancers

Other TRK Programs

  • PRECLINICAL
  • IND ENABLING
  • PHASE I
  • PHASE II
Undisclosed
Undisclosed

Learn More About Pyramid